Clinical trials are a crucial step in the process for new products to reach patients. The information and data those trials yield provide FDA with the evidence to decide whether a product is both safe and effective for the public. But what happens if that crucial information is missing? By only looking at pieces and parts, it’s hard to see the full picture. With out knowing the whole story, could a vital piece of the puzzle be missing? Could missing data put patients at risk?